Effects of Maixuekang Capsules Combined with Edaravone on Serum MMP-9, S-100β Protein Levels and Neurological Functions in Patients with Hemorrhagic Cerebral Infarction

OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral infarction. METHOSDS: A total of 76 patients with hemorrhagic cerebral infarction treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2017 to May 2018 were selected and were randomly divided into treatment group and control group, with 38 patients in each group. The control group was given edaravone, and the treatment group was given Maixuekang Capsules on the basis of the control group. The clinical efficacy, serum MMP-9 and S-100β protein levels, neurological function recovery, activity of daily living and incidence rate of adverse reactions were compared between the 2 groups. RESULTS: The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group(P < 0.05); the National Institutes of Health Stroke Scale(NIHSS) score in the 2 groups decreased(P < 0.05), and the Activity of Daily Living Scale(ADL) score increased(P < 0.05), the improvement of the above 2 scores in the treatment group were better than those in the control group(P < 0.05); the level of MMP-9 was gradually decreasing in the 2 groups, on the 7th day, 14 th day after treatment, and the levels of MMP-9 decreased significantly(P < 0.05), and the treatment group was lower than the control group at all time points(P < 0.05); on the 3rd day after treatment, the levels of S-100β protein in the 2 groups increased significantly(P < 0.05); on the 7th day, 14 th day after treatment, the levels of S-100β protein in the two groups decreased significantly(P < 0.05), and the treatment group was significantly lower than the control group(P < 0.05); there was no significant difference in incidence rate of adverse reactions between 7.89% in the control group and 5.26% in the treatment group(P > 0.05). CONCLUSION: The combination of Maixuekang Capsules and edaravone is effective in treating hemorrhagic cerebral infarction, and it can significantly improve neurological function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.

Effect of human urinary kallikein on the neurological function and intracranial hemodynamics in patients with acute cerebral infarction

Objective:To explore the effect of human urinary kallikein (HUK) on the neurological function and intracranial hemodynamics in patients with acute cerebral infarction.Methods:A total of 150 patients with acute cerebral infarction who were admitted in our hospital were included in the study and divided into the observation group and the control group with 75 cases in each group according to different treatment protocols. The patients in the two groups were given routine drugs for conservative treatment. On this basis, the patients in the observation group were given HUK. NSE and S-100 protein before treatment, 3, 7, 14, and 28 d after treatment in the two groups were compared. TCD was used to detect the cerebral hemodynamics. NIHSS and BI were used to evaluate the improved degree of neurological function and daily living activities before treatment, 1 and 3 months after treatment.Results: NSE and S-100 protein 3, 7, 14, and 28 d after treatment in the observation group were significantly lower than those in the control group (P<0.05). The blood flow rate of left vertebral artery, right vertebral artery, and basilar artery after treatment in the two groups was significantly elevated (P<0.05). The blood flow rate of left vertebral artery, right vertebral artery, and basilar artery after treatment in the observation group was significantly higher than that in the control group (P<0.05). NIHSS and BI scores 1 and 3 months after treatment in the observation group were significantly superior to those in the control group (P<0.05).Conclusions: HUK can effective reduced the brain tissue injury in patients with acute cerebral infarction, and promote the recovery of neurological function, with an accurate efficacy.

依达拉奉对急性脑梗死患者血清SOD、S-100β蛋白的影响

目的探讨依达拉奉对急性脑梗死患者血清SOD、S-100β蛋白的影响。方法将同期收治的71例急性脑梗死患者随机分为治疗组(n=36)和对照组(n=35)。2组均予丹参、肠溶阿司匹林常规治疗,对照组以0.9%氯化钠溶液250 mL+丹参注射液30 mL、0.9%氯化钠溶液250 mL+胞二磷胆碱注射液250 mg静滴,1次.d-1;治疗组在此基础上予依达拉奉注射液30 mg溶于0.9%氯化钠溶液100 mL中静滴,2次.d-1。2组均治疗2个疗程,共14 d,分别于治疗前后记录神经功能缺损评分(CSS量表),评定临床疗效,计算有效率,并于第1、3、7、14日检测血清超氧化物歧化酶(SOD)、S-100β蛋白的水平。结果 2组患者SOD经治疗后均逐渐下降,但治疗后治疗组血清SOD水平均明显高于对照组(P<0.05);2组患者S-100β蛋白均在第3日达到峰值,但治疗组水平明显低于对照组(P<0.01),其后均逐渐降低,2周后S-100β蛋白下降到相同的水平(P>0.05);治疗第14日后2组CSS评分指数较治疗前均明显减少(P<0.01),但治疗组评分少于对照组(P<0.05);2组经治疗后,治疗组有效率高于对照组(P<0.05)。结论依达拉奉能显著改善急性脑梗死患者的神经功能,减少急性脑梗死患者血清SOD消耗量,降低S-100β蛋白水平,对急性脑梗死的神经元有保护作用,其机制为清除自由基、减轻脑缺血及再灌注损伤。